Document Detail

Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer.
MedLine Citation:
PMID:  15655934     Owner:  NLM     Status:  MEDLINE    
Pemetrexed (Alimta) possesses broad antitumor activity. It has been evaluated in non-small-cell lung cancer (NSCLC) as front-line chemotherapy in a comprehensive phase II evaluation. While various antifolates have been previously evaluated in clinical trials, drug development was stopped or delayed in light of their lack of efficacy or occurrence of life-threatening toxicities. While similar trends were observed with pemetrexed early in development, investigators instituted folic acid and vitamin B12 supplementation to minimize these toxicities without hampering drug efficacy. This article briefly summarizes the current evidence that supports the role of pemetrexed-based combinations in clinical trials for chemonaive patients with advanced NSCLC.
Giorgio V Scagliotti; Silvia Novello; Lucio Crino; Rafael Rosell
Related Documents :
18506674 - Response of citrus peelminer marmara gulosa guill?n and davis (lepidoptera: gracillarii...
9834554 - Exploratory studies: implications for drug development in alzheimer's disease.
20215414 - Antibiotics and the social history of the controlled clinical trial, 1950-1970.
24390074 - Designing a simple organic salt-based supramolecular topical gel capable of displaying ...
17286274 - Drug-polymer microparticles produced by supercritical assisted atomization.
10492354 - Intakes of thorium while using thoriated tungsten electrodes for tig welding.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Oncology (Williston Park, N.Y.)     Volume:  18     ISSN:  0890-9091     ISO Abbreviation:  Oncology (Williston Park, N.Y.)     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2005-01-19     Completed Date:  2005-02-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8712059     Medline TA:  Oncology (Williston Park)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  32-7     Citation Subset:  IM    
University of Torino, Department of Clinical & Biological Sciences, S. Luigi Gonzaga Thoracic Oncology Unit, Orbassano (Torino), Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*,  pathology
Cisplatin / administration & dosage
Clinical Trials, Phase II as Topic
Folic Acid Antagonists / administration & dosage*
Glutamates / administration & dosage*
Guanine / administration & dosage*,  analogs & derivatives*
Lung Neoplasms / drug therapy*,  pathology
Neoplasm Metastasis
Thymidylate Synthase / antagonists & inhibitors*
Reg. No./Substance:
0/Folic Acid Antagonists; 0/Glutamates; 137281-23-3/pemetrexed; 15663-27-1/Cisplatin; 73-40-5/Guanine; EC Synthase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pemetrexed in malignant pleural mesothelioma.
Next Document:  Pemetrexed in second-line treatment of non-small-cell lung cancer.